natgillin/translations-raw huggingface dataset:
CRL-9096 (CHOdhfr-) when expressed therein; and/or an amount of bisectingGIcNAc structures on the total carbohydrate structures or on the carbohydrate structures at one particular glycosylation site of the antibody molecule of said antibody molecules in said antibody molecule composition which is at least 20% higher compared to the same amount of antibody molecules in at least one antibody molecule composition of the same antibody molecule isolated from ATCC No. 
CRL-9096 (CHOdhfr-) kada se tamo eksprimira; i/ili (vi) količinu struktura s račvanim GleNAc na ukupnim ugljikohidratnim strukturama ili na ugljikohidratnim strukturama na nekom određenom mjestu glikoziliranja u molekuli protutijela kod navedenih molekula protutijela u navedenom pripravku s molekulom protutijela koja je najmanje 20% veća u usporedbi s istom količinom molekula protutijela u pripravku s najmanje jednom molekulom protutijela za istu molekula protutijela izoliranu iz ATCC No.
Sudden withdrawal from CNS depressant drugs, such as alcohol and benzodiazepines, may also trigger psychotic episodes. 
Iznenadno odvikavanje od CNS deprimirajućih lijekova, poput alkohola i benzodiazepina, može također aktivirati psihotične epizode.
Awning structure according to claim 1, characterized in that the front beam (5) comprises, on at least one of its ends, an end part (50) that is fastened to a vertical wall of a column (7), (8). 
Struktura cerade u skladu s patentnim zahtjevom 1, naznačena time što prednja greda (5) sadrži, na najmanje jednom od svojih krajeva, krajnji dio (50), koji je pričvršćen na okomitu stijenku stupca (7), (8).
The security element according to claim 1, wherein said substrate is selected from the group consisting of transparent substrates carrying printed, coated, or laser-marked indicia, and opaque substrates carrying printed, coated, or laser-marked indicia. 
Sigurnosni element u skladu s patentnim zahtjevom 1, naznačen time, da je navedeni supstrat (1) odabran iz skupine koja se sastoji od transparentnih supstrata koji nose otisnute, premazane ili laserom označene oznake, a neprozirni supstrati nose otisnute, premazane ili laserom označene oznake.
Combination Therapy The compound of the invention may be administered as part of a combination therapy with an agent for treatment of diabetes, obesity, dyslipidaemia or hypertension. 
Uporaba prema zahtjevu 23, naznačena time, da spoj služi kao dio kombinacijske terapije sa sredstvom za liječenje dijabetesa, pretilosti, dislipidemije ili hipertenzije, pri čemu:
The method according to claim 1, wherein the composition is in the form of a food preparation, a dietary supplement, a nutraceutical, or a beverage. 
Sastav za uporabu prema zahtjevu 6, naznačen time, da se oralno davanje primjenjuje u obliku prehrambenog proizvoda, dodatka prehrani, nutritivnog proizvoda ili napitka.
In addition, the ability of this compound to recruit specific co-factors to PPARY ranges from 7 to 24% compared to a PPARY full agonist (set at 100% recruitment: Table 2), thus making the compound of formula III a PPARY partial agonist. 
Uz to, sposobnost ovog spoja da prikupi specifične kofaktore za PPARy kreće se od 7 do 24 % u usporedbi s punim agonistom PPARy (uzeto kao 100 %-tno prikupljanje: Tablica 2), što spoj formule III čini parcijalnim agonistom PPARy.
The compound for use of any of claims 1 to 12, wherein the compound is formulated for administration in combination with a second active agent, and if the hematologic malignancy is mantle cell lymphoma, the second active agent is rituximab, bendamustine, or ibrutinib, or a combination thereof. 
Spoj za uporabu prema bilo kojem od zahtjeva 1 do 12, naznačen time što je spoj formuliran za primjenu u kombinaciji s drugim aktivnim sredstvom, te ako je hematološka maligna bolest limfom plaštenih stanica, drugo aktivno sredstvo je rituksimab, bendamustin, ili ibrutinib, ili njihova kombinacija.
Pharmaceutical, cosmetic and/or dietary composition comprising a mixture of at least three fatty acids selected from palmitic acid, oleic acid, stearic acid, linoleic acid, alpha linolenic acid, gamma linolenic acid, eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), azelaic acid and myristic acid and at least one physiologically acceptable excipient, preferably N-2 hydroxyethyl palmitamide. 
Smjesa najmanje devet masnih kiselina, odabranih od palmitinske kiseline, oleinske kiseline, stearinske kiseline, linolenska kiseline, alfa-linolenske kiseline, gama-linolenske kiseline, eikosapentaenske kiseline (EPA), dokozaheksaenske kiseline (DHA), azelainske kiseline i miristinske kiseline za primjenu u liječenju i/ili prevenciji upalnih patologija odabranih od atopičnog dermatitisa, dermatomiozitis, skleroderme, psorijaze, polimiozitisa, pemfigusa, pemfigoidne bulozne epidermolize, Sjogrenovog sindroma, simpatičke oftalmije, uveitisa, i uveo-retinitisa.
Area percent of atherosclerotic lesions (%) (mean ± s.e.m.) 
Postotak površine ateroskleroznih lezija (%) (prosjek + s.e.m.)
In addition, the method recognises when a subscriber is not attached to a preferred network and is able to instruct the subscribed communications device to automatically detach from the current network and to either attach to an available known more favourable network, or seek connection to a known more favourable network. 
Postupak u skladu s patentnim zahtjevom 2, naznačen time što dodatno uključuje davanje uputa pretplatničkom mobilnom komunikacijskom uređaju (10, 20, 101) da se odvoji od trenutne mreže ako se odredi da to nije mreža kojoj se daje prednost; davanje uputa pretplatničkom mobilnom komunikacijskom uređaju (10, 20, 101) da se ponovno spoji s mrežom kojoj se daje prednost.
The compound of claim 11, wherein the skeletal muscular disorders and diseases are selected from the group consisting of skeletal muscle fatigue, exercise-induced skeletal muscle fatigue, muscular dystrophy, bladder disorders, and incontinence. 
Uporaba prema patentnom zahtjevu 11, naznačena time što su poremećaji i bolesti skeletnih mišića izabrani iz grupe koju čine zamor skeletnog mišića, zamor skeletnog mišića induciran pojačanom fizičkom aktivnošću, mišićna distrofija, poremećaji bešike 1 inkontinencija.
LDPC (Low-density parity-check) encoding Layer 1 signaling data to generate LDPC parity bits; puncturing the generated LDPC parity bits; 
LDPC dekodiranje signalnih podataka LI i zatvorenih LDPC paritetnih bitova; 1 BCH dekodiranje LDPC-dekodiranih signalnih podataka L1 i LDPC paritetnih bitova.
centrifuging the product of step (f) at a rotational speed of at least 2000 rpm, 
(g) filtriranja ili centrifugiranja produkta iz koraka (f),
The method according to any claims 14 to 15 characterized in that only assembly of the modular sandwich panel (1) is executed on the building with already integrated gaskets in longitudinal connection and corner gaskets (6, 7) while transversal gasket (4) is inserted during assembly. 
Postupak prema bilo kom od zahtjeva 14 do 15, naznačen time što se na objektu izvodi samo pričvršćivanje modularnog sendvič panela (1) sa već integriranim brtvama u uzdužnom spoju i kutnim brtvama (6, 7), dok se poprečna brtva (4) ugrađuje tokom montaže.
The method of preparation of alkyl triphenylphosphonium derivatives of tamoxifen of the general formula I is based on a reaction of ylide generated from tert-butyldimethylsilyl-oxy-alkyl-triphenylphosphonium with the general formula II, 
Način pripreme alkil trifenil fosfonijskih derivata tamoksifena opće formule I prema zahtjevu 1 odlikuje se time, da ylid generirani iz tert-butildimefilsili-oksi-alkil-trifenil fosfonija opće formule II,
A method for inhibiting VR1 function in a cell in vitro comprising contacting a cell, capable of expressing VR1 with an effective amount of the compound or a pharmaceutically acceptable salt of the compound of claim 1 or claim 20. 
Postupak za inhibiranje VR1 funkcije u stanici in vitro naznačen time da sadrži kontaktiranje stanice, koja može izražavati VR1, sa učinkovitom količinom spoja ili farmaceutski prihvatljive soli spoja prema zahtjevu 1 ili zahtjevu 20.
The electronic components may be damaged or their function may be impaired by electrostatic discharges. 
Elektronske komponente mogu se oštetiti ili njihova funkcija oslabjeti uslijed elektrostatičkih izboja.
A method of manufacturing a crumb coated food product is disclosed. The method includes the steps of forming an aqueous mixture including a flour mixture having one or more flours; sodium bicarbonate; optional additives selected from processing aids, salts, colorants and, water; adding the mixture into an extruder; adding an aqueous gelling agent to the extruder; extruding the resultant mixture at a temperature greater than 100° C. to form an extrudate; allowing the extrudate to expand to form a porous product; drying the product, and milling the dried product to form a crumb. 
Mrvice za proizvodnju prehrambenih proizvoda sa zrnatom koricom metodom koja obuhvaća korake: formiranje vodene smjese koja sadrži: smjesu brašna koja sadrži jednu ili više vrsta brašna, natrijev hidrogenkarbonat, izborne aditive izabrane između pomoćnih tvari, soli, bojila i vodu; dodavanje smjese u ekstruder; dodavanje vodenog sredstva za geliranje u ekstruder; ekstruzija dobivene smjese pri temperaturi većoj od 100%C da se dobije ekstrudat; pri čemu nakon koraka ekstruzije smjese slijedi korak dodavanja sredstva za geliranje u ekstruder, nakon čega slijedi korak ekstruzije smjese dobivene od smjese brašna i sredstva za geliranje; omogućavanju eksdrudatu da se formira u oblik poroznog proizvoda; sušenje proizvoda, i mljevenje osušenog proizvoda da se dobiju mrvice.
the alcohol is methanol, ethanol or isopropanol; and/or 
(a) alkohol je metanol, etanol ili izopropanol; i/ili
In using a compound of the Formula I for therapeutic or prophylactic purposes it will generally be administered so that a daily dose in the range, for example, 0.1 mg/kg to 75 mg/kg body weight is received, given if required in divided doses. 
Tijekom upotrebe spoja prikazanog Formulom I za terapeutske ili profilaktičke potrebe, navedeni će se spoj davati po potrebi u nekoliko manjih doza i na takav način da dnevna primljena doza bude u rasponu od, na primjer, 0.1 mg/kg do 75 mg/kg tjelesne težine.
arranging technical installations within said cuboid shape, and providing interior equipment within said cuboid shape; 
(iv) organizirajući tehničke instalacije (16, S) unutar navedenog kuboidnog oblika,
optionally wherein the second GFRa3 antagonist is a small organic molecule, a polypeptide antagonist, a second antibody specific for GFRa3, a siRNA or an antisense molecule specific for GFRa3; or wherein the cytokine or cytokine receptor antagonist is an interleukin-1(IL-1) antagonist, an IL-6 antagonist, or an IL-18 antagonist. 
opcionalno naznačeno time, što drugi antagonist GFRa3 jest mala organska molekula, antagonist polipeptida, drugo antitijelo specifično za GFRa3, siRNA ili antisens molekula specifična za GFRa3; ili naznačeno time, što antagonist citokina ili receptora citokina jest antagonist interleukina-1 (IL-1), antagonist IL-6 ili antagonist IL-18.
Rest and impurities due to smelting, wherein the material has a hardness of at least 46 to 48 HRC. 
0,007 kao i nečistoće zbog taljenja, gdje materijal za navedenu toplinski obrađenu cijev za projektile ima tvrdoću od najmanje 46 do 48 HRC.
a pusher limit switch (37. 
- < graničnu sklopku potiskivača (37.
Compounds of the formula I as claimed in one or more of claims 1 to 23 for use in the treatment and/or prevention of disorders in which insulin resistance is involved. 
. Spojevi formule I u skladu s jednim ili više patentnih zahtjeva 1 do 23, namijenjeni upotrebi u liječenju i/ili sprječavanju poremećaja kod kojih je uključena otpornost na inzulin.
In particular, it is believed that the compounds of the present invention provide an anti-tumour effect by way of inhibition of EGFR and/or erbB2 receptor tyrosine kinases. 
Konkretno, smatramo da spojevi iz ovog izuma postižu antitumorski efekt na način da inhibiraju EFGR i/ili erbB2 receptorske tirozin kinaze.
The human T cell of claim 16, wherein the CAR is encoded by a nucleic acid sequence comprising SEQ ID NO:8. 
(vi) CAR je kodirana sekvencom nukleinske kiseline naznačenom u sekvenci SEQ ID NO:8
The dimethyl fumarate or monomethyl fumarate for use as in any one of claims 7 to 11, wherein the dimethyl fumarate or monomethyl fumarate is to be administered to the subject for at least 12 weeks. 
Dimetil fumarat ili monometil fumarat za upotrebu kao u bilo kojem zahtjevu od 7 do 11, naznačen time da se dimetil fumarat ili monometil fumarat daje osobi tijekom najmanje 12 tjedana.
Pharmaceutical composition If required, a molecule or a vector expressing an antisense oligonucleotide of the invention can be incorporated into a pharmaceutically active mixture or composition by adding a pharmaceutically acceptable carrier. 
Farmaceutski sastav obuhvaća besmisleni oligonukleotid kako je definiran u bilo kojem od patentnih zahtjeva 1-14 i/ili vektor iz patentnog zahtjeva 15, farmaceutski prihvatljivi nosač.
The image processing apparatus according to claim 1 or 2, wherein the image processing apparatus performs image processing so as the anisotropic blur image (P2) to be subtracted from the band image (a,B,Y) more largely than the isotropic blur image (P1) as the edge reliability (E) corresponding to the pixel to be processed becomes higher. 
Uređaj za obradu slike prema zahtjevu 1 ili 2, naznačen time, da uređaj za obradu slike izvodi obrađivanje slike tako, što se neizotropna zamagljena slika (P2) treba odbiti iz slike na traci (a, B, y) puno opsežnije nego izotropna zamagljena slika (P1), kako pouzdanost rubova (E) odgovarajuća za piksel koji se treba obraditi, postaje veća.
The control method according to any one of claims 13 to 21, characterized in that when a vehicle applied with the hybrid drive system is in the braking deceleration energy recycling mode, the second motor (3) and/or the first motor (2) perform energy recycling when the vehicle is braking, and in this mode, the first motor (2) and/or the second motor (3) are controlled to generate electricity. 
Postupak upravljanja prema bilo kojem od zahtjeva 13 do 21, naznačena time, da kada je vozilo primijenjeno s hibridnim pogonskim sustavom način rada za recikliranje energije usporavanjem kočnice, drugi motor (3) i/ili prvi motor (2) obavljaju recikliranje energije pri kočenju vozila, a u tom načinu upravljaju prvi motor (2) i/ili drugi motor (3) za generiranje struje.
4th Extraction of the Aqueous Layer: 
Datum podnošenja europske prijave patenta:
A conjugate comprising a fusion protein to transport a brain effector entity across the blood brain barrier of claims 21 to 25 and a brain effector entity coupled to a N-terminal end of the CH2-CH3 Ig entity of the fusion protein by a linker. 
Konjugat, naznačen time, da obuhvaća fuzijski protein za prijenos entiteta moždanog efektora preko moždano-krvne barijere prema zahtjevima 18 ili 19, te entitet moždanog efektora spojen s N-terminalnim krajem entiteta CH2-CH2-Ig od fuzijskog proteina putem povezivača.
The compound according to claim 1, wherein R4 and R5 taken together with the nitrogen atom to which they are attached form piperidine, piperazine or morpholine, which are optionally substituted one or more times with methyl, ethyl, phenyl or N′-acetyl. 
R,1i Rs, uzeti zajedno s atomom dušika na kojeg su vezani, tvore piperidin, piperazin ili morfolin, izborno jednom ili višestruko supstituirane s metilom, etilom, fenilom ili acetilom; ili
A nitroxyl donor for use in a method of treating pulmonary hypertension, which method comprises administering to a mammal in need thereof an effective amount of the nitroxyl donor, wherein the nitroxyl donor is a compound of formula (III): or a pharmaceutically acceptable salt thereof, wherein: 
Donor nitroksila za primjenu u metodi liječenja plućne hipertenzije, pri čemu metoda sadrži administriranje kod sisavaca kojima je potrebna efikasna količina darova nitroksila, gdje je donor nitroksila spoj formule (III): e 13 "3 oi |
A compound according to claim 1, which is an acid addition salt of (E)-3-[1-(4-dimetylaminomethyl-benzenesulfonyl)-1H-pyrrol-3-yl]-N-hydroxy-acrylamide with any acid selected from the group consisting of phosphoric acid, maleic acid, oxalic acid, malonic acid and methanesulphonic acid, or a hydrate thereof. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time što je kiselinska adicijska sol (£)-3-[1-(4- dimetilaminometilbenzensulfonil)-177-pirol-3-11]-N-hidroksiakrilamida s bilo kojom od kiselina koje se bira iz skupine koju čine fosforna kiselina, maleinska kiselina, oksalna kiselina, malonska kiselina i metansulfonska kiselina, ili njegov hidrat.
The method of claim 3, wherein the isolated monoclonal antibody is an IgG1 or IgG2 antibody. The method of claim 1, wherein the isolated monoclonal antibody is a fully human antibody, a humanized antibody, or a chimeric antibody. 
Monoklonsko protutijelo ili njegov antigen-vezujući fragment prema bilo kojem od patentnih zahtjeva 1 do 4, naznačeno time što je monoklonsko protutijelo ili njegov antigen-vezujući fragment potpuno ljudsko protutijelo, humanizirano protutijelo, kimerno protutijelo, ili njihov fragment koji veže antigen.
or a substitution of at least the five amino acid residues: F243L, R292P, Y300L, V305I and P396L; 
(E) zamjene najmanje pet aminokiselinskih ostataka: F243L, R292P, Y300L, V305I i P396L; gdje se navedeno obrojčavanje provodi prema Kabatovoj shemi obrojčavanja.
The precipitation is filtered, washed with TBME/heptane 1:1 (v/v) and dried in vacuum. 
Precipitat se filtrira, ispere se sa TBME/heptanom 1: 1 (v/v) i suši u vakuumu.
wherein in above formulae R1 is hydrogen or a nitrogen protecting group. 
Pf3-a) pri čemu u gornjim formulama R1 je vodikova ili dušikova zaštitna skupina.
a multi-functional crosslinking agent which is at least one selected from the group consisting of a nonpolymeric polyacid and an anhydride and optionally 
višefunkcionalno sredstvo za križno povezivanje, od kojih se najmanje jedno izdvaja iz grupe, koje se sastoji od nepolimernih poliacida i anhidrida i po izboru,
A pharmaceutical composition comprising an effective amount of a conjugate comprising a targeting peptide and a cytokine, wherein the targeting peptide is a peptide containing a NGR, isoDGR or RGD motif and wherein the cytokine is TNFa or TNFB, together with pharmaceutically acceptable carriers and diluents, for use in the treatment of mesothelioma. 
Farmaceutski pripravak koji sadrži djelotvornu količinu konjugata koji sadrži ciljni peptid i citokin, gdje je ciljni peptid peptid koji sadrži motiv NGR, izoDGR ili RGD, a citokin je TNFa ili TNFB, uz farmaceutski prihvatljive podloge i razrjeđivače, naznačen time što je namijenjen upotrebi u liječenju mezotelioma.
The composition as claimed in claim 9, wherein the microparticles of buprenorphine are presented upon the surfaces of the water-soluble carrier particles. 
Tableta prema bilo kojem od zahtjeva 3 do 6, pri čemu su čestice limunske kiseline predstavljene 1 ponašaju se kao čestice nosača.
A compound according to claim 1, which is selected from or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a polymorph, or a solvate thereof. 
S "oca OCH, ou O ili njegov stereoizomer, tautomer, farmaceutski prihvatljiva sol, polimorf, ili solvat.
A pharmaceutical composition comprising an aqueous solution consisting essentially of from about 80 mg/ml to about 120 mg/ml levofloxacin or ofloxacin and from about 175 mM to about 225 mM of a divalent or trivalent cation selected from the group consisting of magnesium, calcium, zinc, copper, aluminum, and iron; wherein the solution has a pH from about 5 to about 7 and an osmolality from about 300 mOsmol/kg to about 500 mOsmol/kg. 
Aerosol za uporabu sukladno patentnom zahtjevu 1, pri čemu se otopina u osnovi sastoji od koncentracije levofloksacina od 90 mg/ml do 110 mg/ml, koncentracije magnezij klorida od 180 mM do 220 mM, pH od 5 do 7, osmolalnosti od 300 mOsmol/kg do 500 mOsmol/kg, i nedostaje mu laktoza.
Transdermal delivery systems of fentanyl, another opioid antagonist, are commercially available, e.g., under the name Duralgesic. 
Sustavi transdermalnog davanja fentanila, drugog opioidnog antagonista, dostupni su na tržištu, npr., pod imenom "Duralgesic".
The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof, for use according to any one of claims 1 to 4, 5, or 6; wherein said sundown syndrome is afternoon sundown syndrome. 
Spoj prema bilo kojem od zahtjeva 1 do 4, ili njegova farmaceutski prihvatljiva sol, za uporabu prema bilo kojem od zahtjeva 1 do 4, 5 ili 6, naznačen/a time, da se kod sundown-sindroma radi o popodnevnom sundown-sindromu.
The process according to any one of claims 6 to 13, wherein the compound of Formula III is present at an amount varying from about 0.5 to about 50 moles per mole of compound of Formula IIa. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time što navedeni spoj formule III dolazi u rasponu količina od otprilike 0,5 do otprilike 50 mol/mol spoja formule II.
The aqueous formulation of claim 5 comprising 0.2 to 1 µg lixisenatide per U insulin glargine. 
Vodena formulacija u skladu s patentnim zahtjevom 3, naznačena time što sadrži 0,2 µg do 1 µg liksisenatida po jedinici inzulin glargina.
The pharmaceutical composition according to claim 10, wherein diabetes is insulin-dependent diabetes mellitus (type I diabetes) or non-insulin-dependent diabetes mellitus (type II diabetes). 
Spoj prema zahtjevu 14 ili 15, naznačen time da dijabetes je dijabetes melitus ovisan o inzulinu (dijabetes tip I) ili dijabetes melitus koji nije ovisan o inzulinu (dijabetes tip II).
In some embodiments, the present invention provides a method for assaying a Clostridium botulinum neurotoxin (BoNT) for activity, comprising: a) contacting a hiPS derived neuronal cell with a composition comprising a BoNT; and b) assaying the BoNT for biological activity. 
Postupak procjene neurotoksina iz bakterije Clostridium botulinum (BoNT) na aktivnost, naznačen time što se sastoji u: a) stavljanju u kontakt živčane stanice nastale iz ljudske inducirane pluripotentne matične stanice (hiPS) s pripravkom koji sadrži BoN'T; i b) procjeni navedenog BoNT na biološku aktivnost.
The compound for use of claim 23, or a pharmaceutically acceptable salt form thereof, wherein said compound is administered in the form of a transdermal patch, ointment, lotion, cream, or gel. 
Spoj za uporabu prema zahtjevu 6, naznačen time da je navedeni spoj za davanje u obliku transdermalnog flastera, masti, losiona, kreme ili gela.
is 1 to 4 amino acid residues in length; is 2 to 15 amino acid residues in length; and L4 is 2 to 15 amino acid residues in length; 
je duljine 7 ostataka amino kiseline; je duljine 5 ostataka amino kiseline; je duljine 1 ostatak amino kiseline; i
In a specific embodiment, the k locus comprises a contiguous sequence of the human λ locus that spans from Vλ3-29 to Vλ3-1, and a contiguous sequence of the human λ locus that spans from Vλ5-52 to Vλ1-40. 
Cc) graničnu sekvenciju humanog lokusa lakog A lanca koja se proteže od hVA5-52 do hV2A1-40 1 graničnu sekvenciju humanog lokusa lakog X lanca koja se proteže od hVA3-29 do hV23-1.
1440 8.58 QL: the concentration below which formula (II) cannot be precisely quantified (which was estimated experimentally to be 1.71 ng/mL). 
2,99 1440 8,58 QL: koncentracija ispod koje se formula (II) ne može precizno kvantitativno odrediti (koja je eksperimentalno procijenjena na 1,71 ng/mL).
The pharmaceutical composition according to claim 25, which is applied to lung cancer, kidney cancer, urothelial cancer, colorectal cancer, prostate cancer, glioblastoma multiforme, ovarian cancer, pancreatic cancer, breast cancer, melanoma, liver cancer, bladder cancer, gastric cancer, cervical cancer, head and neck cancer, or esophageal cancer. 
Farmaceutska kompozicija u skladu sa patentnim zahtjevom 18, za primjenu u metodi za liječenje raka pluća, raka bubrega, urotelijalnog raka, kolorektalnog raka, raka prostate, glioblastoma multiforme, raka jajnika, raka gušterače, raka dojke, melanoma, raka jetre, raka mjehura, raka želuca, cervikalnog raka, raka glave i vrata, ili raka jednjaka.